Targeted Killing of Cancer Cells in Vivo and in Vitro with EGF-Directed Carbon Nanotube-Based Drug Delivery
University of Connecticut · National Institutes of Health · +3 more institutions
Abstract
Carbon nanotube-based drug delivery holds great promise for cancer therapy. Herein we report the first targeted, in vivo killing of cancer cells using a drug-single wall carbon nanotube (SWNT) bioconjugate, and demonstrate efficacy superior to nontargeted bioconjugates. First line anticancer agent cisplatin and epidermal growth factor (EGF) were attached to SWNTs to specifically target squamous cancer, and the nontargeted control was SWNT-cisplatin without EGF. Initial in vitro imaging studies with head and neck squamous carcinoma cells (HNSCC) overexpressing EGF receptors (EGFR) using Qdot luminescence and confocal microscopy showed that SWNT-Qdot-EGF bioconjugates internalized rapidly into the cancer cells.…
Citation impact
- FWCI
- 35.86
- Percentile
- 100%
- References
- 58
Authors
10- ABAshwin BhirdeCorresponding
University of Connecticut
- VPVyomesh Patel
National Institutes of Health, National Institute of Dental and Craniofacial Research
- JGJulie Gavard
National Institute of Dental and Craniofacial Research, National Institutes of Health
- GZGuofeng Zhang
National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health
- AAAlioscka A. Sousa
National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health
Topics & keywords
- In vivo
- Cisplatin
- Cancer cell
- Epidermal growth factor
- Drug delivery
- Cancer research
- Head and neck squamous-cell carcinoma
- Epidermal growth factor receptor